Please use this identifier to cite or link to this item:
|Title:||Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk||Authors:||Feldt-Rasmussen, B.
El Nahas, M.
El Nahas, M.
|Issue Date:||Jul-2007||Citation:||Feldt-Rasmussen, B., Lange, M., Sulowicz, W., Gafter, U., Kar, N.L., Wiedemann, J., Christiansen, J.S., El Nahas, M., Sulkova, S., Feldt-Rasmussen, B., Madsen, M., Hannedouche, T., Lai, K.N., Holtzman, E., Gafter, U., Schwartz, D., Katzir, Z., Weissgarten, J., Majdan, M., Niemczyk, S., Sulowicz, W., Lee, K.O., Ahlmen, J., El Nahas, M., Mitra, S., Rodger, R.S.C., Tapson, J.S., Rustom, R., Ayub, W., Mikhail, A., Thomas, M. (2007-07). Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. Journal of the American Society of Nephrology 18 (7) : 2161-2171. ScholarBank@NUS Repository. https://doi.org/10.1681/ASN.2006111207||Abstract:||Nutritional markers, such as lean body mass (LBM) and serum albumin, predict outcome in dialysis patients, in whom protein-energy malnutrition is associated with increased morbidity and mortality. The metabolic effects of human growth hormone (hGH) may improve the nutritional and cardiovascular health of these patients and consequently reduce morbidity and mortality. The aim of this study was to establish clinical proof of concept of hGH treatment for the improvement of the nutritional status in adult patients who are on maintenance hemodialysis. A total of 139 adult patients who were on maintenance hemodialysis and had serum albumin levels ≤40 g/L were randomly assigned to 6 mo of treatment with placebo or 20, 35, or 50 μg/kg per d hGH. Change in LBM and serum albumin (primary outcomes), health-related quality of life, and secondary efficacy and safety parameters were monitored. The study showed that hGH treatment increased LBM significantly at all dosage levels (2.5 kg [95% confidence interval 1.8 to 3.1] versus -0.4 kg [95% confidence interval -1.4 to 0.6]; P < 0.001 for pooled hGH groups versus placebo). Serum albumin tended to increase (P = 0.076), serum transferrin (P = 0.001) and serum HDL (P < 0.038) increased, and plasma homocysteine was reduced (P = 0.029). TNF-α also tended to decrease with treatment (P = 0.134). An improvement in the Role Physical SF-36 quality-of-life subscale was observed (P = 0.042). There were no differences in clinically relevant adverse events between groups. In conclusion, hGH therapy safely improves LBM, other markers of mortality and morbidity, and health-related quality of life in adult patients who are on maintenance hemodialysis. A long-term study is warranted to investigate whether these treatment benefits result in reduced mortality and morbidity. Copyright © 2007 by the American Society of Nephrology.||Source Title:||Journal of the American Society of Nephrology||URI:||http://scholarbank.nus.edu.sg/handle/10635/132799||ISSN:||10466673||DOI:||10.1681/ASN.2006111207|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 23, 2020
WEB OF SCIENCETM
checked on Oct 14, 2020
checked on Oct 17, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.